Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis

• Published in: Journal of gastroenterology and hepatology Vol. 36; no. 9; pp. 2397 - 2407
• Main Authors: Yao, Jiaqi, Jiang, Xinchan, You, Joyce H S
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.09.2021
• Subjects: adalimumab; Adalimumab - therapeutic use; Child; Cost-Benefit Analysis; cost‐effectiveness analysis; Crohn Disease - drug therapy; Crohn's disease; Drug Monitoring; Gastrointestinal Agents - therapeutic use; Humans; Markov chains; Monoclonal antibodies; Patients; Pediatrics; Remission; Remission (Medicine); Sensitivity analysis; therapeutic drug monitoring; Crohn's disease; cost-effectiveness analysis; adalimumab; therapeutic drug monitoring; pediatrics

Background and Aim Recent clinical findings showed proactive therapeutic drug monitoring (TDM) of adalimumab (ADL) to improve sustained remission rate in pediatric patients with Crohn's disease (CD). The present study aimed to evaluate the potential cost‐effectiveness of proactive versus reacti...